Communiqués SpringWorks Therapeutics, Inc.

Actions

SWTX

US85205L1070

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 30/06/2025			Varia. 5j.	Varia. 1 janv.
46,99 ^USD	+0,02%		-.--%	-

15/12	Immunome bondit après des résultats prometteurs pour son traitement contre les tumeurs desmoïdes
01/12	Tyra Bioscience nomme Bhavesh Ashar au poste de directeur des opérations	MT

Communiqués

21/10/25	SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology	GL
21/10/25	SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology	GL
18/08/25	European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors	GL
18/08/25	European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors	GL
18/07/25	European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN	GL
18/07/25	European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN	GL
20/06/25	SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors	GL
03/06/25	SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX	BU
25/05/25	SpringWorks Therapeutics reçoit un avis favorable du CMUH pour l’utilisation du mirdamétinib pour le traitement des patients adultes et pédiatriques atteints de NF1-PN	GL
23/05/25	SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN	GL
09/05/25	SpringWorks Therapeutics: Q1 Earnings Snapshot	AQ
30/04/25	SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX	BU
28/04/25	Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business	GL
27/04/25	SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union	GL
27/04/25	SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union	AQ
20/02/25	SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates	GL
19/02/25	SpringWorks Therapeutics and Jewelry Designer Jennifer Fisher Team Up to Encourage People with Desmoid Tumors to Take Action Before Their Tumor Takes Over	PR
12/02/25	SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN	GL
30/01/25	SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025	GL
13/01/25	SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference	GL
06/01/25	SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference	AQ
03/01/25	SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference	GL
26/11/24	SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference	AQ
26/11/24	SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference	GL
12/11/24	SpringWorks Therapeutics : Reports Third Quarter 2024 Financial Results and Recent Business Highlights Form 8 K	PU